Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
Titel:
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
Auteur:
Catenacci, Daniel V T Kang, Yoon-Koo Park, Haeseong Uronis, Hope E Lee, Keun-Wook Ng, Matthew C H Enzinger, Peter C Park, Se Hoon Gold, Philip J Lacy, Jill Hochster, Howard S Oh, Sang Cheul Kim, Yeul Hong Marrone, Kristen A Kelly, Ronan J Juergens, Rosalyn A Kim, Jong Gwang Bendell, Johanna C Alcindor, Thierry Sym, Sun Jin Song, Eun-Kee Chee, Cheng Ean Chao, Yee Kim, Sunnie Lockhart, A Craig Knutson, Keith L Yen, Jennifer Franovic, Aleksandra Nordstrom, Jeffrey L Li, Daner Wigginton, Jon Davidson-Moncada, Jan K Rosales, Minori Koshiji Bang, Yung-Jue